Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antisnake venom serum is a biological therapeutic agent used to treat envenomation caused by snake bites. It is composed of polyclonal antibodies, typically IgG or F(ab')2 fragments, purified from the plasma of animals (usually horses or sheep) that have been immunized with specific snake venoms. The serum works by binding to and neutralizing the toxic proteins and enzymes in the venom, such as neurotoxins, phospholipases, and metalloproteinases, thereby preventing or reversing systemic toxicity. Lexicare Pharma is a developer and manufacturer of this serum, which is often produced in a polyvalent form to provide broad coverage against the most clinically significant venomous snakes in a particular region, such as the Indian Cobra, Common Krait, Russell's Viper, and Saw-scaled Viper.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antisnake venom serum.